Evaluation of total phenolic contents and antioxidant activities in different solvent extracts of Diospyros melanoxylon Roxb. bark

Antibacterial and anticardidal activities from the polar and non-polar solvent extracts of Diospyros melanoxylon Roxb. is established earlier. Here we have evaluated amount of total phenolics present in Aqueous, Methanol, Ethanol, Acetone, Ethyl acetate, and Chloroform solvents by using Folin-ciocaltuaeu reagent from Diospyros melanoxylon Roxb. bark. Anti-oxidative potential of phenolics present in different solvents were evaluated by DPPH free radical scavenging assay, O-phenanthroline assay and reducing power assay. It was observed that the Methanol is a better solvent for the total phenolics extraction. The amount of phenolics present in solvents were in the order of Methanol > Ethanol > Acetone > Aqueous > Ethyl acetate. The highest free radical scavenging potential 59.33 ± 1.52% was observed in Ethanol extract and the lowest scavenging potential 39.66 ± 1.52% in Aqueous extract. The highest scavenging potential 66.66 ± 2.4% was observed in Acetone extract in case of O-phenanthroline assay. The similar scavenging potential was observed in Aqueous, Methanol, Ethanol and Acetone extracts in case of reducing power assay. This study shows that the Diospyros melanoxylon Roxb. bark extract could be used as probable antioxidative agent

Proteinase inhibitors of pigeonpea cv. BSMR 736: Characterization and bioefficacy against Helicoverpa armigera

Pigeonpea is an agriculturally important leguminous crop with high vulnerability to insect pest attack specifically, Helicoverpa armigera. The proteinase inhibitors (PIs) mediated host plant resistance against insect pests is a promising sustainable agricultural research practice. The current study was carried out to perceive biochemical characterization of proteinase inhibitors named PPTI in the pigeonpea (cv. BSMR 736). The purification of PPTI from crude protein seed extract was achieved by acetone precipitation, N-LP-IEF, and trypsin affinity chromatography. It was found to inhibit bovine trypsin and HaGPs in vitro. The optimal conditions for inhibition were pH 8 and temperature 40ºC. The PPTI showed four isoinhibitors bands on native, non-reducing and reducing SDS-PAGE in the range of 26.7–19.3 KDa. Upon resolution on two-dimensional gel electrophoresis (2-DE), PPTI produced nine pI variant spots having isoelectric point (pI) 6.6, 6.6, 6.3, 6.1, 5.9, 5.8, 5.7, 5.6 and 5.6. An artificial diet containing PPTI reduced the H. armigera larval weight about 69%, with 25% mortality. For eco-friendly sustainable agricultural practices, natural compounds like PPTI could be expressed in transgenic crops to prevent the invasion of H. armigera in pigeonpea

Infuence of chemically synthesized copper nanoparticles and cupric ions on oxalate oxidation system in germinating Sorghum grain

We have earlier reported the effects of chemically synthesized copper nanoparticles (CuNPs) on oxalate oxidase (OxOx) activity, extracted from the shoot tissue of germinating grain sorghum i.e. in vitro. Here, we tried to study this effect in vivo and compare it with those of Cu2+. We describe herein, characterization of CuNPs and their effects on oxalate oxidation system i.e. OxOx activity, total oxalate and H2O2 content in vivo i.e. in shoot tissues/leaves of germinating grain Sorghum (Sorghum vulgare L). To achieve it, grain sorghum seeds were grown up to 10 days in laboratory, irrigated with Hoagland’s solution containing either CuNPs (1.0 ppm) or Cu2+ (1.0 ppm) after 4 days of germination. Control were irrigated with Hoagland solution only. The shoot/leaves of the seedling plants were harvested at 4, 6, 8 and 10 day of germination and analysed quantitatively for OxOx activity, soluble protein, H2O2 and total oxalate. The growth of the Sorghum seedling plants supplemented with CuNPs and Cu2+ was decreased significantly (P <0.1) at all growth stages compared to control. This inhibitory effect of CuNPs was higher than Cu2+. CuNPs decreased the activity of OxOx but Cu2+ had no effect at day 10. Both CuNPs and Cu2+ decreased the specific activity of OxOx and H2O2 content but increased total oxalate content at day 10. The decrease in H2O2 content in both CuNPs and Cu2+ supplemented shoot tissues with concomitant increase in oxalate content confirmed the decreased activity of OxOx in CuNPs and Cu2+ supplemented seedling plants

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402